Bitcoin

Mainstream coverage will focus on the medical breakthrough, but for crypto this is a non-event unless it triggers a broader rotation out of risk-off positions into equities. Given that biotech/pharma is a separate sector, the capital flows are unlikely to shift meaningfully into or out of crypto based on this single development.

A new drug has been reported to functionally cure many hepatitis B virus infections, based on an article published in Science.

Hepatitis B Cure Lands in Science — DeSci Tokens Could Be the Real Crypto Takeaway

Hepatitis B Cure Underscores the Value of Decentralized Science (DeSci) as a Faster Path to Medical Breakthroughs

Crypto markets are currently in a fear-driven, low-volume environment (F&G 38) where altcoins underperform BTC. Non-crypto scientific news rarely moves prices unless it triggers a broader risk-off/on shift, which this does not. The market's attention remains on Fed policy, stablecoin flows, and BTC dominance trends.

HIV-1 triggers receptor-mediated signalling during cell–cell spread to remodel nuclear pores and overcome a bottleneck in resting T cell infection.